Last reviewed · How we verify
Y90 Ibritumomab Tiuxetan RIT — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Y90 Ibritumomab Tiuxetan RIT (Y90 Ibritumomab Tiuxetan RIT) — Sunnybrook Health Sciences Centre.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Y90 Ibritumomab Tiuxetan RIT TARGET | Y90 Ibritumomab Tiuxetan RIT | Sunnybrook Health Sciences Centre | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Y90 Ibritumomab Tiuxetan RIT CI watch — RSS
- Y90 Ibritumomab Tiuxetan RIT CI watch — Atom
- Y90 Ibritumomab Tiuxetan RIT CI watch — JSON
- Y90 Ibritumomab Tiuxetan RIT alone — RSS
Cite this brief
Drug Landscape (2026). Y90 Ibritumomab Tiuxetan RIT — Competitive Intelligence Brief. https://druglandscape.com/ci/y90-ibritumomab-tiuxetan-rit. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab